2025-02-252019-07-05https://repositorio.cmmg.edu.br/handle/123456789/94Introduction: Intraperitoneal chemotherapy (IPC) is a highly complex process of drug delivering with curative intent to carefully selected patients with advanced peritoneal carcinomatosis (PC). Objective: This study aimed to evaluate the use of IPC, in a real-life setting, and assess the patient’s profile and outcomes. Method: A retrospective descriptive study was performed through the analysis of medical charts of patients hyperthermic intraperitoneal chemotherapy (HIPEC) or early postoperative intraperitoneal chemotherapy. Eligible patients presented ECOG performance status scores of 0 or 1 and peritoneal metastasis. Results: Twenty-six patients, with 72% of females, and the mean age of 55.19±11.21 were included. Ovarian cancer (50%), pseudomyxoma peritonei (34.6%), and colorectal cancer (15.3%) were the most common primary tumors. The individuals in the HIPEC group presented better ECOG score compared to the EPIC group (76.2% vs. 20%). In 92.3% of the cases, IPC was indicated as rescue therapy for relapsed tumors; in 57.6% of the cases, it was delivered after a second recurrence. Patients with pseudomyxoma peritonei (7.6%) received HIPEC as primary therapy after cytoreductive surgery. Only subjects with ovarian cancer receiver EPIC (19.2% of the included patients), all after a second recurrenThere was no difference in time to progression, considering HIPEC or EPIC treatments. Conclusion: Although complex, peritonectomy combined with IPC can be performed in referral centers with acceptable levels of morbidity and mortalityAcesso abertoQuimioterapia intraperitoneal, Quimioterapia intraperitoneal hipertermica, Quimioterapia intraperitoneal pós-operatória precoce, Carcinomatose peritoneal; Intraperitoneal chemotherapy, Hyperthermic intraperitoneal chemotherapy, Early postoperative intraperitoneal Chemotherapy; Peritoneal carcinomatosis.Dissertação4.01.00.00-6 - Medicina